Clonal Dynamics of Chronic Lymphocytic Leukaemia Treated with Pirtobrutinib after Previous Treatment with Zanubrutinib (NCT06812715)

This is a multicentre single-arm prospective phase II trial evaluating pirtobrutinib in the treatment of relapsed/refractory (R/R) Chronic Lymphocytic Leukaemia (CLL) patients who have previously received zanubrutinib, and to specifically evaluate Bruton Tyrosine Kinase (BTK) mutational status (clonal dynamics) before, during and after treatment with pirtobrutinib.

Trial phase

Phase 2

Trial participation type

This trial has been designed for the Clinical Research of a Drug.

Principal investigator

Prof Constantine Tam

Key inclusion data

Confirmed diagnosis of CLL; Prior systemic therapy, which must include zanubrutinib as the most recent prior line of therapy; Patients must have received at least one cycle (28 days) of zanubrutinib; Patients must have an indication for second- or subsequent-line treatment; Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2. Additional inclusion and exclusion criteria applies, please contact trial team for more information.